EAU 2017: State-of-the-art Lecture: Is There Still a Role for Chemotherapy?
London, England (UroToday.com) Dr. Aristotle Bamias from Greece had the important role of delivering the State-of-the-Art Lecture on “Is There Still a Role for Chemotherapy?” for bladder urothelial carcinoma in the era of Immuno-oncology at today’s EAU 2017 annual congress.
EAU 2017: Lymph node dissection is not associated with increased 30-day complication among patients undergoing radical nephrectomy for renal cell carcinoma: a propensity-score based analysis
London, England (UroToday.com) The role of lymph node dissection (LND) at the time of radical nephrectomy (RN) is controversial because its oncologic benefit is unclear. Notably, there is little information on complication rates associated with LND to inform clinical risk-benefit analyses.
EAU 2017: Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?
London, England (UroToday.com) At present, partial nephrectomy (PN) is strongly indicated in patients with stage III or worse (GFR < 60) chronic kidney disease (CKD). However, PN remains a relative indication for patients with stage II CKD (GFR 60-89). The authors compared renal functional and survival outcomes for patients with baseline stage II CKD who underwent PN or radical nephrectomy (RN).
EAU 2017: Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)
London, England (UroToday.com) The management of metastatic urothelial carcinoma is undergoing rapid changes. With the introduction of immunotherapy, chemotherapy is no longer the only option.
EAU 2017: Familial and genetic factors: New SNPs and panels
London, England (UroToday.com) Prostate cancer has normal distribution in the population. The challenge is to find and treat the more aggressive disease and hopefully not treat the low risk disease. In this presentation Professor Eeles described the new OncoArray chip, identifying 65 small nucleotide polymorphisms (SNPs) correlated with prostate cancer.
EAU 2017: Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling
London, England (UroToday.com) Usage of liquid biopsy to assess tumor behavior in men with metastatic castration-resistant prostate cancer (mCRPC) is a major clinical need. The investigators developed a circulating tumor cell (CTC) based platform for analysis of whole blood samples in mCRPC patients.
EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials
London, England (UroToday.com) At this morning’s EAU 2017 thematic session on Immuno-oncology, Dr. Laurence Albiges provided a very educational presentation on current open questions and trials ongoing in the immune therapy setting for renal cell carcinoma. Dr. Albiges started her talk by delineating first, second and third line treatment and making the argument that fourth line treatment should focus on drugs not previously given, especially nivolumab or cabozantinib.